SUN-PROTECTIVE CLOTHING REGULATION AS MEDICAL DEVICE QUESTIONED
This article was originally published in The Gray Sheet
Executive SummarySUN-PROTECTIVE CLOTHING REGULATION AS MEDICAL DEVICE QUESTIONED by Robert O'Holla, vice president of regulatory affairs at Johnson & Johnson, at a Sept. 21 meeting of FDA's General and Plastic Surgery Devices Advisory Panel. O'Holla, the industry representative to the panel, said FDA is not exercising appropriate "discretion" in choosing to regulate sun-protective clothing at a time when it lacks "the resources to handle some of our more important technological breakthroughs."
You may also be interested in...
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.